Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd. (SCNI) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
scni · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Scinai Immunotherapeutics Ltd.You SCNI | $1M | N/A | — | -$3.56 |
 Azitra, Inc. AZTR | $2M | N/A | — | -$2.25 |
 Enveric Biosciences, Inc. ENVB | $1M | N/A | — | -$36.24 |
 Indaptus Therapeutics, Inc. INDP | $4M | N/A | — | -$21.58 |
 Jasper Therapeutics, Inc. JSPR | $7M | N/A | — | -$3.95 |
 Onconetix, Inc. ONCO | $0M | N/A | — | -$4.28 |
 Psyence Biomedical Ltd. PBM | $0M | 14.15x | — | $1.78 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Scinai Immunotherapeutics Ltd. (SCNI) measures how much investors pay for each dollar of the company's trailing earnings. SCNI's current PE ratio of N/A is calculated by dividing its stock price of $0.38 by its TTM earnings per share of -$3.56.
Frequently asked questions
SCNI pe ratio · 6 questionsSCNI's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.38 and TTM EPS of -$3.56. Data sourced from Financial Modeling Prep via SCNI's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Scinai Immunotherapeutics Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09